Predicting the maximum-tolerated dose of PNU-159548 (4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin) in humans using CFU-GM clonogenic assays and prospective validation

Author： Moneta D.   Geroni C.   Valota O.   Grossi P.   de Jonge M.J.A.   Brughera M.   Colajori E.   Ghielmini M.   Sessa C.  

Publisher： Elsevier

ISSN： 0959-8049

Source： European Journal of Cancer, Vol.39, Iss.5, 2003-03, pp. : 675-683

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors

By Choi Brian   Alberti Dona   Schelman William   Kolesar Jill   Thomas James   Marnocha Rebecca   Eickhoff Jens   Ivy S.   Wilding George   Holen Kyle  

Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 5, 2010-10 ,pp. : 973-980

Springer Publishing Company

Access to resources Recommend Favorite

PNU-159548, a novel cytotoxic antitumor agent with a low cardiotoxic potential

By Della Torre Paola   Podestà Arturo   Imondi Anthony R.   Moneta Donatella   Sammartini Umberto   Arrigoni Claudio   Terron Andrea   Brughera Marco  

Cancer Chemotherapy and Pharmacology, Vol. 47, Iss. 4, 2001-04 ,pp. : 355-360

Springer Publishing Company

Access to resources Recommend Favorite

Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents

By Kurtzberg Leslie   Roth Stephanie   Bagley Rebecca   Rouleau Cecile   Yao Min   Crawford Jennifer   Krumbholz Roy   Schmid Steven   Teicher Beverly  

Cancer Chemotherapy and Pharmacology, Vol. 64, Iss. 5, 2009-10 ,pp. : 1029-1038

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours

By de Jonge M.J.A.   Verweij J.   van der Gaast A.   Valota O.   Mora O.   Planting A.S.T.   Mantel M.A.   Bosch S.V.D.   Lechuga M.J.   Fiorentini F.   Hess D.   Sessa C.  

European Journal of Cancer, Vol. 38, Iss. 18, 2002-12 ,pp. : 2407-2415

Elsevier

Access to resources Recommend Favorite

Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1

By Edlund Per   Ahlgren Johan   Bjerre Karsten   Andersson Michael   Bergh Jonas   Mouridsen Henning   Holmberg Stig B.   Bengtsson Nils-Olof   Jakobsen Erik   Møøller Susanne   Lindman Henrik   Blomqvist Carl  

Acta Oncologica, Vol. 50, Iss. 3, 2011-04 ,pp. : 329-337

Informa Healthcare

Access to resources Recommend Favorite